
|Articles|March 4, 2014
- Vol 31 No 3
- Volume 31
- Issue 3
Data Point
Author(s)Richard M. Berlin, MD
Three years deep in despair, he’s swallowed every pill I prescribed...
Advertisement
While reviewing the results of a drug study for treatment-resistant depression
Three years deep in despair, he’s swallowed
every pill I prescribed. Refusing ECT,
his family and I convinced him to give
research medication one last shot.
Unblinded data arrived today and glows
on my computer screen, each depressed
patient’s response graphed with a dot,
the experimental molecule clearly beating
placebo, my patient’s outlier point six feet under
the rising line of success, a speck of coal
on a snow-covered field, my mind expanding
the insignificant dot to a skull’s eye socket
staring me down like a Beretta’s bullet hole.
Articles in this issue
over 12 years ago
The New CPT Codes: Ethical Challenges in a New Billing Era?over 12 years ago
End-of-Life Decisions: Who Decides and the Role of the Psychiatristover 12 years ago
Revive Flurothyl Inhalation Therapyover 12 years ago
Prescribing Psychotropics for Women of Childbearing Potentialover 12 years ago
Introduction: The Brave New World of Psychiatric Ethicsover 12 years ago
Ethics and Virtues in Clinical PsychiatryAdvertisement
Related to this article

UK AD-SMART platform trial speeds Alzheimer disease treatment discovery by testing multiple repurposed drugs at once across NHS sites, aiming to protect memory and quality of life.

When an antidepressant seems to stop working, the patient’s deterioration is real. The explanation may be less certain.

The evidence points toward an overall protective effect in adult cohorts and no increase in completed suicide in younger populations.

A psychiatry resident and APA Diversity Leadership Fellow explains how social history, open talk about stigma, and bilingual videos can widen access to care.

Phase 2 data show RAP-219 eases acute bipolar mania with significant YMRS gains and encouraging tolerability, setting the stage for FDA talks and phase 3 plans.

Explore evolving ethical challenges of long-acting injectable antipsychotics, weighing relapse prevention against coercion, stigma, incentives, and racial equity in clinical practice.

Neurocrine launches a phase 2 trial of once-daily NBI-'567, testing a selective muscarinic agonist to boost cognition in mild to moderate Alzheimer disease.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Psych Consult: TSH Testing in New-Onset Depression. An Endocrinologist’s Guidance for Psychiatrists
2
ADHD Medications for Managing Menopausal Brain Fog: Improvements in Subjective Executive Function
3
New Phase 2 Data on Bezisterim for the Treatment of Long COVID
4
What Do Patient-Level Studies Tell Us About Antidepressants and Suicide Risk?
5

